期刊文献+

肾癌术后的生物免疫治疗新进展 被引量:5

下载PDF
导出
摘要 大多数肾癌对化疗和放疗不敏感,相对预后较差,目前仍缺乏有效的治疗手段。随着基因技术、肿瘤免疫、分子生物技术的迅速发展,免疫治疗成为较有前景的一种治疗肿瘤的方法,人们对免疫治疗寄予厚望。免疫治疗是以激发机体的免疫功能,达到控制和消灭肿瘤细胞的一种治疗方法。应用免疫细胞、肿瘤疫苗、免疫基因等方法治疗肾癌已取得了很大的进展,相信在不久的将来,肾癌免疫治疗将获得突破性的进展,终将成为临床治疗手术后肾癌患者的主要手段。
作者 闫东 袁超英
出处 《现代泌尿外科杂志》 CAS 2012年第4期422-424,共3页 Journal of Modern Urology
  • 相关文献

参考文献20

  • 1COPPIN C, PORZSOI.T F, AWA A, et al. Immunotherapy for advanced renal cell cancer [J]. Cochrane Database Syst Rev, 2006,25 (1) :1420-1425.
  • 2ESCUDIER B,CHVEREAU C, LASSET C, et al. Cytokines in metastatic renal cell carcinoma:is it useful to switch to interleu- kin-2 or interferon after failure of a first treatment? Grope Fan- caisd Irrimunotherapy [J]. Clin Oncol, 2008,17 : 2039-2043.
  • 3NEGRIER S,ESCUDIER B, LASSET C,et al. Recombinant hu- man interleukin-2 recombinant human interferonalfa-2a or both in metastatic renal cell careinoma[J]. Engl J Med, 2008, 338: 1272-1278.
  • 4KUENEN BC, TABERNERO J, BASELGA J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patient with advanced renal cell carcinoma melanoma and soft tis- sue sarcoma [J]. Clin Cancer Res,2007,9(5) :1648-1655.
  • 5LARA P N JR,QUINN D I,MARGOLIN K. SU5416 plus inter- feron alpha in advanced renal cell carcinoma a phase imaging cor- relates of angiogenesis inhibition [J]. Clin Cancer Res, 2006,9 (130) :4772-4781.
  • 6YANG J C, HAWORTH L,SHERRY R M. A randomized trial of bevacizumabfor metastatic renal cancer [J]. Engl J Med, 2006,349(5):427-434.
  • 7ROSENBERG SA, LOTZE MT, YANG JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunc- tion with lymphokine-aetivated killer cells for the treatment of patients with advanced cancer[J ]. J Nati Cancer Inst, 2007,85 (8) : 622-632.
  • 8张力建,陈晋峰,柯杨,Robert E Mansel,Wen G Jiang.荧光实时定量PCR检测NSCLC中PEDF基因表达状态的研究[J].中国肺癌杂志,2006,9(2):177-181. 被引量:4
  • 9CHILD R, SPROULE J, DRAPER S, et al. Performance of a psychomotor skill following rest exercise at the plasma epineph- rine threshold and maximal intensity exercise[J]. New Engl J Med, 2008,343 : 750-758.
  • 10SCHAAP N,SCHAT TENBERG A,BAER B,et al. Induction of graft-versus-leukemia to prevent relapse after partially lympho- cyte-depleted allogenee bone marrow transplantation by pre- emptive donor leukocyte infusions[J]. Leukemia, 2007,15 (9) 1339-1346.

二级参考文献22

  • 1付琛,蒋国梁,王丽娟,等.放射治疗非小细胞肺癌的临床Ⅲ期试验[J].中华放射肿瘤学杂志,1994,16(4):306-309.
  • 2Jeremic B,Shibamoto Y,Milicic B,et al.Concurrent radiochemotherapy for patients with stage Ⅲ non-small-cell lung cancer:Long-term results of a phase Ⅱ study[J].Int J Radiat Oncol Biol Phys,1998,42:1091-1096.
  • 3Rosell R,Felip E.Role of multimodality treatment for lung cancer[J].Semin Surg Oncol,2000,18:143-151.
  • 4Byhardt RW,Scott C,Sause WT,et al.Response,toxicity,failure patterns,and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemocherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung[J].Int J Radiat Oncol Biol Phys,1998,42:469-478.
  • 5Movsas B,Scott C,Sause W,et al.The benefit of treatment intensification Ⅰ sage and histology-dependent in patients with locally advanced non-small-cell lung cancer (NSCLC):A quality-adjusted survival analysis of Radiation Therapy Oncology Group (RTOG) chemoradiation studies[J].Int J Radiat Oncol Biol Phys,1999,45:1143-1149.
  • 6Saunders M,Dische S,Barrett A,et al.Continuous,hyperfractionated,accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer:mature data from the randomised multicentre trial.CHART Steering Committee[J].Radiother Oncol,1999,52:137-148.
  • 7Komaki R,Scott CB,Byhardt R,et al.Failure patterns by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four radiation therapy oncology group (RTOG) studies in inoperable non-small-cell lung cancer (NSCLC)[J].Int J Radiat Oncol Biol Phys,1998,42:263-267.
  • 8Mehta M,Scrimger R,Mackie R,et al.A new approach to dose escalation in non-small-cell lung cancer.[J] Int J Radiat Oncol Biol Phys,2001,49(1):23-33.
  • 9Hayman JA,Martel MK,Ten Haken,et al.Dose escalation in non-small-cell lung cancer using three-dimensional conformal therapy:update of a phase Ⅰ trial[J].J Clin Oncol,2001,19:127-136.
  • 10Wu Q,Mohan R.Multiple local minima in IMRT optimization based on dose-volume criteria[J].Med Phys,2002,29(7):1514-1527.

共引文献20

同被引文献60

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部